Keyphrases
Breast Cancer
55%
Triple-negative Breast Cancer
54%
Neoadjuvant Chemotherapy
22%
Pathological Complete Response
22%
Metastatic Breast Cancer
19%
Chemotherapy
17%
Confidence Interval
16%
Circulating Tumor DNA (ctDNA)
14%
Breast Cancer Patients
14%
Neoadjuvant
14%
Tumor
13%
Breast Cancer Risk
13%
Clinical Outcomes
13%
Palbociclib
11%
Young Women
11%
Estrogen Receptor-positive Breast Cancer
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Racial Differences
9%
Trastuzumab
9%
Overall Survival
9%
Neoadjuvant Therapy
9%
Breast
9%
African American
9%
Clinical Trials
8%
Eribulin
8%
Phase II Study
8%
Axillary Ultrasound
8%
Breast Cancer Susceptibility
8%
Diffuse Optical Tomography
8%
Phase II Trial
8%
Patients with Breast Cancer
7%
Carboplatin
7%
Genetic Testing
7%
Hazard Ratio
7%
Clinical T1
7%
T1-T2
7%
Susceptibility Loci
7%
Estrogen Receptor-negative
6%
High Risk
6%
Early Breast Cancer
6%
Invasive Breast Cancer
6%
Sentinel Lymph Node Biopsy
6%
Poor Prognosis
6%
Proteogenomics
6%
Response to Neoadjuvant Chemotherapy
6%
Postmenopausal Women
6%
European Ancestry
6%
Anastrozole
5%
ErbB2
5%
HER2-negative Metastatic Breast Cancer
5%
Medicine and Dentistry
Breast Cancer
100%
Triple Negative Breast Cancer
40%
Neoplasm
30%
Neoadjuvant Chemotherapy
27%
Malignant Neoplasm
18%
Circulating Tumor DNA
14%
Metastatic Breast Cancer
12%
Disease
10%
Palbociclib
8%
Gene Mutation
8%
Radiomics
8%
Optical Tomography
8%
Recurrent Disease
8%
Clinical Trial
8%
Biological Marker
8%
Race Difference
8%
Estrogen Receptor
8%
Sentinel Lymph Node Biopsy
7%
Cancer Risk
7%
Trastuzumab
6%
Overall Survival
6%
Lung Cancer
6%
Clinical Stage
6%
Neoadjuvant Therapy
6%
Oncologist
6%
Phase II Trials
6%
Anastrozole
5%
Metastatic Carcinoma
5%
Genetic Screening
5%
Lobular Carcinoma
5%
Cancer Susceptibility
5%
Oncotype DX
5%